The $505M Backdoor to Wall Street That Biotech Can't Stop Talking About

Those names matter. RA Capital and Venrock don't throw half a billion dollars at something because of a slick pitch deck. They do serious diligence, and the fact that they led this round (Venrock was also part of Candid's original $370 million Series A) signals genuine conviction in the science.

Combined with existing cash, the company says it's funded through 2030. Four years of runway is almost unheard of for a newly public biotech. Most companies spend their first year as a public entity worrying about their next capital raise. Candid gets to actually focus on, you know, making drugs.

What Candid Is Actually Building

Candid develops something called T-cell engagers (TCEs), which are essentially molecular matchmakers. They grab a T-cell (one of your immune system's attack dogs) with one hand and a disease-causing cell with the other, forcing an introduction that ends badly for the target.

The company is using these TCEs to go after autoimmune diseases, conditions where the immune system attacks the body's own tissues. Their lead drug, cizutamig, targets a protein called BCMA found on certain immune cells that drive autoimmune conditions. It's already been given to approximately 80 patients, with around 40 of those in autoimmune settings. Phase 2 trials are expected to start later in 2026 for myasthenia gravis (a muscle-weakening disease) and a type of interstitial lung disease linked to rheumatological conditions.

But cizutamig isn't the only card in the deck. A second candidate, CND261, targets CD20 (a different protein on immune cells) and has been dosed in over 100 patients across both cancer and autoimmune indications. Early data shows it can deplete B-cells deep in tissue with low rates of cytokine release syndrome, a dangerous inflammatory reaction that has plagued similar drugs.

There's also CND319, which targets both CD19 and CD20 simultaneously. Think of it as a double-barreled approach to wiping out harmful immune cells. First-in-human studies are planned for mid-2026.

The Bigger Picture: Reverse Mergers Are Having a Moment

Candid isn't the only company sneaking through the back door to Wall Street. Nanyang Biologics announced a reverse merger via SPAC valued at $1.5 billion, with closing expected by mid-2026. Veraxa Biotech has also signaled plans for a SPAC-style listing.

The appeal is straightforward: traditional IPOs require a friendly market, extensive regulatory paperwork, and a costly roadshow where you essentially beg institutional investors to buy in at a price they set. Reverse mergers let you control the timeline, lock in your valuation, and arrive on public markets with committed capital already in hand.

Of course, not every reverse merger works out. The route has historically attracted some questionable companies that couldn't survive the IPO vetting process. But Candid is a different animal entirely. It has a proven CEO, blue-chip investors, a pipeline with human data, and enough cash to last half a decade. The reverse merger wasn't a sign of weakness; it was a strategic choice.

The Ken Song Factor

You can't tell this story without talking about the man behind it. Ken Song served as CEO of RayzeBio, a radiopharmaceutical company, which was acquired by Bristol Myers Squibb for $4.1 billion. That kind of exit buys you credibility (and investor phone calls returned immediately).

He launched Candid in 2024, building it through the acquisitions of two companies: Vignette Bio and TRC 2004. The leadership team includes Arvind Kush as CFO, who also served as CFO at RayzeBio and previously worked in healthcare banking at Bank of America. When both the science lead and the money lead have a successful exit under their belts, investors tend to pay attention.

So What Does This Mean?

Candid's reverse merger is a proof of concept for a path that many biotechs have been eyeing nervously. If your science is strong, your investors are committed, and your team has a track record, you don't need to wait for the IPO window to open. You can build your own door.

The real test comes next. Phase 2 data on cizutamig will determine whether this is a $505 million bet that pays off or just an expensive science experiment. But with cash through 2030, multiple shots on goal across several drug candidates, and a CEO who's done this before, Candid is about as well-positioned as a newly public biotech can be.

The IPO market may be cautious. Candid clearly isn't.

GSK's $690M Itch Drug Has Two Weeks to Prove It Was Worth the Price

Alfasigma just paid $300 million upfront for GSK's late-stage itch drug, with an FDA decision landing in just two weeks. The deal could reach $690 million if everything goes right, but the clock is ticking on the biggest "if" in specialty pharma.